Princess Margaret Cancer Centre
@pmresearch-uhn.bsky.social
The Princess Margaret Cancer Centre is Canada’s largest integrated cancer research, teaching, and treatment centre, one of the top cancer research centres in the world and is one of the University Health Network’s six research institutes.
New study shows oral combo of enasidenib + venetoclax helps 62% of patients with IDH2 mutated, relapsed or refractory #AML achieve remission. Safe, effective, and outpatient-friendly. Led by our Drs. Steven Chan & Guillaume Richard-Carpentier.
@thelancethaem.bsky.social:
doi.org/10.1016/S235...
@thelancethaem.bsky.social:
doi.org/10.1016/S235...
November 11, 2025 at 3:30 PM
New study shows oral combo of enasidenib + venetoclax helps 62% of patients with IDH2 mutated, relapsed or refractory #AML achieve remission. Safe, effective, and outpatient-friendly. Led by our Drs. Steven Chan & Guillaume Richard-Carpentier.
@thelancethaem.bsky.social:
doi.org/10.1016/S235...
@thelancethaem.bsky.social:
doi.org/10.1016/S235...
A real-world study validates the LSC17 score's ability to predict AML patient outcomes and identify high-risk patients who may benefit from more aggressive treatments, led by Drs. Jean Wang @uhn.ca, Tracy Murphy & Stanley Ng.
doi.org/10.3324/haem...
@uhnresearch.ca
doi.org/10.3324/haem...
@uhnresearch.ca
July 10, 2025 at 6:03 PM
A real-world study validates the LSC17 score's ability to predict AML patient outcomes and identify high-risk patients who may benefit from more aggressive treatments, led by Drs. Jean Wang @uhn.ca, Tracy Murphy & Stanley Ng.
doi.org/10.3324/haem...
@uhnresearch.ca
doi.org/10.3324/haem...
@uhnresearch.ca
Rethinking Novel Therapy Use in End-of-Life Cancer Care
Research from @zimmteamlab.bsky.social @uhn.ca reports a rising use of systemic anticancer therapies at the end of life—primarily driven by cancer immunotherapy. This trend raises important concerns.
doi.org/10.1200/JCO-...
@uhnresearch.ca
Research from @zimmteamlab.bsky.social @uhn.ca reports a rising use of systemic anticancer therapies at the end of life—primarily driven by cancer immunotherapy. This trend raises important concerns.
doi.org/10.1200/JCO-...
@uhnresearch.ca
June 11, 2025 at 12:23 PM
Rethinking Novel Therapy Use in End-of-Life Cancer Care
Research from @zimmteamlab.bsky.social @uhn.ca reports a rising use of systemic anticancer therapies at the end of life—primarily driven by cancer immunotherapy. This trend raises important concerns.
doi.org/10.1200/JCO-...
@uhnresearch.ca
Research from @zimmteamlab.bsky.social @uhn.ca reports a rising use of systemic anticancer therapies at the end of life—primarily driven by cancer immunotherapy. This trend raises important concerns.
doi.org/10.1200/JCO-...
@uhnresearch.ca
Immune Cells Speak the Brain’s Language
In a groundbreaking series of studies, our scientists have uncovered the intricate crosstalk between immune system and nervous system—impacting the development of cancer, autoimmune diseases, tissue regeneration and skin health.
@uhnresearch.ca @uhn.ca
In a groundbreaking series of studies, our scientists have uncovered the intricate crosstalk between immune system and nervous system—impacting the development of cancer, autoimmune diseases, tissue regeneration and skin health.
@uhnresearch.ca @uhn.ca
June 9, 2025 at 2:18 PM
Immune Cells Speak the Brain’s Language
In a groundbreaking series of studies, our scientists have uncovered the intricate crosstalk between immune system and nervous system—impacting the development of cancer, autoimmune diseases, tissue regeneration and skin health.
@uhnresearch.ca @uhn.ca
In a groundbreaking series of studies, our scientists have uncovered the intricate crosstalk between immune system and nervous system—impacting the development of cancer, autoimmune diseases, tissue regeneration and skin health.
@uhnresearch.ca @uhn.ca